Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
7
|
| gptkbp:bfsParent |
gptkb:Vesicare
|
| gptkbp:activities |
muscarinic receptor antagonist
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
gptkb:Vesicare
|
| gptkbp:category |
gptkb:C
|
| gptkbp:class |
anticholinergic agent
|
| gptkbp:clinical_trial |
Phase III
treatment of overactive bladder |
| gptkbp:community_service |
not established
|
| gptkbp:contraindication |
gptkb:sneaker
gptkb:Insurance_Company urinary retention |
| gptkbp:dosage_form |
gptkb:tablet
|
| gptkbp:effective_date |
gptkb:2004
|
| gptkbp:excretion |
urine
|
| gptkbp:frequency |
once daily
|
| https://www.w3.org/2000/01/rdf-schema#label |
solifenacin
|
| gptkbp:indication |
urge incontinence
urinary frequency urinary urgency |
| gptkbp:ingredients |
gptkb:solifenacin_succinate
C23 H26 N2 O2 |
| gptkbp:interacts_with |
gptkb:ketoconazole
gptkb:digoxin gptkb:rifampicin |
| gptkbp:is_atype_of |
G04 B D08
|
| gptkbp:is_available_on |
generic drug
|
| gptkbp:is_effective_against |
improves quality of life
reduces urinary incontinence episodes |
| gptkbp:is_used_for |
overactive bladder
|
| gptkbp:lifespan |
45 hours
|
| gptkbp:manager |
oral
|
| gptkbp:manufacturer |
gptkb:Astellas_Pharma
|
| gptkbp:metabolism |
liver
|
| gptkbp:pharmacokinetics |
highly protein-bound
inhibits acetylcholine at muscarinic receptors |
| gptkbp:research |
ongoing studies for long-term effects
studies on dosage optimization studies on combination therapy studies on efficacy in men studies on efficacy in women |
| gptkbp:safety_features |
may cause drowsiness
use with caution in elderly patients not recommended for patients with severe hepatic impairment |
| gptkbp:side_effect |
constipation
dry mouth blurred vision urinary retention |
| gptkbp:storage |
room temperature
|
| gptkbp:type_of |
174840-51-0
|
| gptkbp:type_of_care |
once daily dosing improves adherence
|